Leading the Development of Systemically Deliverable Oncolytic Immunotherapies.
Adze Biotechnology is developing a platform of immunotherapies that treat solid tumors and develop a robust anti-tumor immunity for patients.
About
Adze Biotechnology is engaged in the development of immunotherapies that treat tumors while engaging patient immune systems for durable responses.
Science
Our approach is based on our novel oncolytic backbone which enables systemic delivery to tumors previously inaccessible to these types of therapies.
Pipeline
We have a broad and growing pipeline of drugs which can deliver checkpoint inhibitors directly into tumors.
Our immunotherapies turn cold tumors hot while delivering immune-modulating payloads to create durable anti-cancer responses.
Our Vision
Our vision is to build an immunotherapy company based on our differentiated oncolytic viral backbone. Our backbone can deliver immunotherapy payloads systemically or via intra-tumoral administration to tumors.
Our Strategy
The company is focused on converting its significant platform advantage into multiple drug candidates and to continue building strategic partnerships with major pharma that will add value over the long term.
Learn about Adze Oncolytic Immunotherapies
Adze’s growing platform of oncolytic immunotherapies features systemic delivery retargeted sub platforms, and an ability to enhance anti-PD-1 therapy performance.
01.
Capable of systemic or intratumoral delivery
02.
Multiple solid tumor indications
03.
Delivery of enhanced anti-PD-1 payloads
We turn cold tumors hot and make tumors visible to the patient’s immune system.
Adze Biotechnology is developing a growing platform of immunotherapies that utilize our proprietary and targeted oncolytic viral backbone. Our oncolytic backbone enables systemic delivery of immunotherapies and checkpoint inhibitors that self-amplify (conditionally replicate) locally in tumors.
Adze Biotechnology latest news:
Adze Biotechnology and King’s College London Announce Clinical Collaboration in hard-to-treat Breast Cancer
Our goal is to harness the potential of ADZE1.C to reprogram the tumor microenvironment and activate systemic anti-tumor immunity. Dr. Paola Grandi, CSO Adze
Adze Biotechnology Submits Bellberry HREC Application for Adze1.C Clinical Trial in Australia
Adze Biotechnology, Inc. announced today the submission of a Human Research Ethics Committee (HREC) application to Bellberry Limited in Australia for the company’s Phase 1 clinical trial of Adze1.C in patients with metastatic melanoma.
Paola Grandi, PhD, MBA, Joins Adze Biotechnology to Lead Pre-Clinical and Translational Research Programs.
ADZE is thrilled to welcome Dr. Paola Grandi to our team as we advance our pipeline of systemically deliverable oncolytic immunotherapies into the clinic.”— Sidney Hopps, Chief Executive Officer of Adze
ADZE Biotechnology Reports US Patent Office Grants Patent Claiming Novel Recombinant Adenovirus
This Notice of Allowance for broad recombinant adenovirus claims is another important step forward for ADZE, which further strengthens and expands our intellectual property portfolio.”— Sidney Hopps, Chief Executive Officer of ADZE
Adze Biotechnology Announces Members of Scientific Advisory Board
“The Adze Scientific Advisory Board will provide important counsel in the years ahead, with research & development”, Sidney Hopps, Co-Founder & CEO Adze CORAL
Adze Biotechnology Completes $6.2 Million First Closing of Series A Financing
“This first close of our Series A furthers our mission of bringing potentially life-saving treatments to patients in need.” – Sidney Hopps, Co-Founder & CEO